Juul sues FDA over documents supporting e cigarette ban
Juul sues FDA over documents supporting e-cigarette ban
Sections
Axios Local
Axios gets you smarter faster with news & information that matters
About
Subscribe
Juul sues FDA over documents supporting e-cigarette ban
Juul Labs tobacco- and menthol-flavored vaping e-cigarette products are displayed in a convenience store. Photo: Patrick T. Fallow/AFP via Getty Images Juul Labs on Tuesday filed a lawsuit against the Food and Drug Administration over the agency's refusal to disclose documents supporting its order to take in the U.S. market. The big picture: The FDA in June ordered Juul to take its e-cigarettes off the market saying the company hadn’t submitted enough evidence that they were safe. But the after a federal appeals court granted Juul a temporary stay on the order. Details: Juul accused the FDA of violating the Freedom of Information Act by withholding a majority of the "scientific disciplinary reviews" underlying the sales ban, according to the filed in a court in Washington, D.C.Juul alleges the FDA denied the FOIA requests, invoking the deliberative process privilege to withhold the majority of those materials."Withholding the disciplinary reviews that would answer these questions impedes JLI’s ability to seek appropriate relief from [the] FDA’s decision and is also completely at odds with the purpose of FOIA and the transparency Congress expects from administrative agencies," the complaint alleges."The public deserves a complete picture of the scientific facts behind one of the agency’s most controversial and closely scrutinized decisions in recent years, especially where even FDA recognizes its order is suspect." What they're saying: “We took this necessary action as we remain concerned about the inequitable treatment of our applications given the political pressure on the agency to reach a specific result," a Juul spokesperson told Axios in an emailed statement."This action will help us obtain information about the FDA review of our applications relevant to our continued appeal of the agency’s decision,” the spokesperson added.The FDA declined to comment on ongoing litigation. Go deeper: Editor's note: This story has been updated with additional details.